VAY736

Monoclonal antibody

Phase 3Mechanism not established
Phase 3underway

Evidence outlook · registrational

Sjögren's Disease: registrational readout pending

Its supporting mid-stage studies have completed. Registrational readout expected around 2029-08-15.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (12)
Sjögren's Disease
NCT07621809 · Novartis Pharmaceuticals
2026-07-16 – 2033-08-14 · Sjögren´s Disease
What this study did
NCT05349214 · Novartis Pharmaceuticals
2022-08-04 – 2027-04-15 · Sjogren Syndrome
What this study did
NCT05350072 · Novartis Pharmaceuticals
2022-07-28 – 2026-06-02 · Sjogren Syndrome
What this study did
Other / comorbidity
NCT06711887 · Novartis Pharmaceuticals
2025-05-19 – 2035-08-01 · Lupus Nephritis
What this study did
NCT06133972 · Novartis Pharmaceuticals
2024-05-21 – 2034-10-02 · Systemic Lupus Erythematosus
What this study did
NCT05985915 · Novartis Pharmaceuticals
2023-10-27 – 2033-04-22 · Sjogrens Syndrome
What this study did
NCT05126277 · Novartis Pharmaceuticals
2022-07-14 – 2031-02-04 · Lupus Nephritis
What this study did
NCT05624749 · Novartis Pharmaceuticals
2023-04-21 – 2029-04-09 · Systemic Lupus Erythematosus
What this study did
NCT05639114 · Novartis Pharmaceuticals
2023-03-02 – 2029-03-23 · Systemic Lupus Erythematosus
What this study did
NCT05648968 · Novartis Pharmaceuticals
2022-12-30 – 2028-12-19 · Warm Autoimmune Hemolytic Anemia (wAIHA)
What this study did
NCT05653349 · Novartis Pharmaceuticals
2023-02-03 – 2028-08-11 · Primary Immune Thrombocytopenia (ITP)
What this study did
NCT05653219 · Novartis Pharmaceuticals
2023-02-02 – 2028-04-08 · Primary Immune Thrombocytopenia
What this study did
Phase 2/3 (1)
Other / comorbidity
NCT03217422 · Novartis Pharmaceuticals
2018-02-15 – 2025-12-17 · Autoimmune Hepatitis
What this study did
Phase 2 (14)
Sjögren's Disease
NCT02962895 · Novartis Pharmaceuticals
2017-06-27 – 2021-09-23 · Primary Sjogren Syndrome
What this study did
NCT02149420 · Novartis Pharmaceuticals
2014-05-23 – 2018-02-07 · Primary Sjögren's Syndrome
What this study did
Other / comorbidity
NCT06470048 · Novartis Pharmaceuticals
2024-10-09 – 2034-07-31 · Diffuse Cutaneous Systemic Sclerosis
What this study did
NCT07660172 · Novartis Pharmaceuticals
2027-02-08 – 2033-04-22 · Primary Immune Thrombocytopenia (ITP)
What this study did
NCT07421167 · Novartis Pharmaceuticals
2026-08-04 – 2030-08-31 · Primary Immune Thrombocytopenia (ITP), Primary Evans Syndrome (ES)
What this study did
NCT07039422 · Novartis Pharmaceuticals
2026-06-26 – 2030-08-30 · Primary Immune Thrombocytopenia, Warm Autoimmune Hemolytic Anemia
What this study did
NCT05885555 · Novartis Pharmaceuticals
2023-08-16 – 2029-03-19 · Primary Immune Thrombocytopenia (ITP)
What this study did
NCT06293365 · Novartis Pharmaceuticals
2024-07-02 – 2029-01-16 · Sjögrens Disease, Systemic Lupus Erythematosus, Rheumatoid Arthritis
What this study did
NCT03827798 · Novartis Pharmaceuticals
2019-02-27 – 2026-09-11 · Hidradenitis Suppurativa
What this study did
NCT05124925 · Novartis Pharmaceuticals
2022-07-27 – 2026-01-05 · Sjogren Syndrome
What this study did
NCT03656562 · Novartis Pharmaceuticals
2018-12-19 – 2025-04-28 · Systemic Lupus Erythematosus (SLE)
What this study did
NCT03287414 · Novartis Pharmaceuticals
2017-12-20 – 2022-02-14 · Idiopathic Pulmonary Fibrosis
What this study did
NCT01930175 · Novartis Pharmaceuticals
2013-12-18 – 2019-09-25 · Pemphigus Vulgaris
What this study did
NCT02038049 · Novartis Pharmaceuticals
2013-12-20 – 2018-09-13 · Relapse Remitting Multiple Sclerosis
What this study did
Phase 1/2 (1)
Sjögren's Disease
NCT02495129 · Novartis Pharmaceuticals
2015-12 – 2017-09 · Primary Sjögren's Syndrome
What this study did
Phase 1 (6)
Other / comorbidity
NCT06411639 · Novartis Pharmaceuticals
2024-11-25 – 2028-06-24 · Sjogren Disease, Systemic Lupus Erythematosus
What this study did
NCT04903197 · Novartis Pharmaceuticals
2022-01-24 – 2025-02-24 · Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma
What this study did
NCT03574545 · Novartis Pharmaceuticals
2018-12-19 – 2024-07-18 · Rheumatoid Arthritis
What this study did
NCT03400176 · Novartis Pharmaceuticals
2018-04-09 – 2023-09-29 · Chronic Lymphocytic Leukemia (CLL)
What this study did
NCT02675803 · Novartis Pharmaceuticals
2010-12-20 – 2018-01-22 · Rheumatoid Arthritis
What this study did
NCT02137889 · Novartis Pharmaceuticals
2012-07 – 2012-11 · Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
What this study did

Competitive landscape

This drug's own stage for Sjögren's Disease: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
VAY736: this drugPhase 3Monoclonal antibody—not yet gradedNo reviewed efficacy summary in this indication
Deucravacitinib (Sotyktu)Phase 3Small moleculeTYK2not yet gradedNo reviewed efficacy summary in this indication
TelitaciceptPhase 3Protein / enzyme therapeuticBAFF / APRILPartial signal
NCT05673993: Primary endpoint, ESSDAI change at week 24 vs placebo: met; the release gives no figures (RemeGen, 2025-08-13).
ImeroprubartPhase 2Monoclonal antibodyFcRnnot yet gradedNo reviewed efficacy summary in this indication
MRT-6160Phase 2Small moleculeVAV1not yet gradedNo reviewed efficacy summary in this indication
ABBV-319Phase 1Antibody–drug conjugateCD19not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(10 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow VAY736 to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (4)
March 2027 (1)
Phase 3Systemic Lupus ErythematosusActive not recruiting
Est. primary completion 2027-03-26 · NCT05639114 · CT.gov ↗
What to watch
April 2027 (1)
Phase 3Systemic Lupus ErythematosusActive not recruiting
Est. primary completion 2027-04-12 · NCT05624749 · CT.gov ↗
What to watch
July 2027 (1)
Phase 2Diffuse Cutaneous Systemic SclerosisActive not recruiting
Est. primary completion 2027-07-30 · NCT06470048 · CT.gov ↗
What to watch
September 2027 (1)
Phase 3Lupus NephritisActive not recruiting
Est. primary completion 2027-09-21 · NCT05126277 · CT.gov ↗
What to watch
2029 (2)
January 2029 (1)
Phase 2Primary Immune Thrombocytopenia (ITP), Primary Evans Syndrome (ES)Recruiting
Est. primary completion 2029-01-18 · NCT07421167 · CT.gov ↗
What to watch
August 2029 (1)
Phase 3Sjögren's DiseaseRecruiting
Est. primary completion 2029-08-15 · NCT07621809 · CT.gov ↗
What to watch
2033 (2)
April 2033 (2)
Phase 2Primary Immune Thrombocytopenia (ITP)Not yet recruiting
Est. primary completion 2033-04-22 · NCT07660172 · CT.gov ↗
What to watch
Phase 3Sjogrens SyndromeActive not recruiting
Est. primary completion 2033-04-22 · NCT05985915 · CT.gov ↗
What to watch
2034 (1)
April 2034 (1)
Phase 3Systemic Lupus ErythematosusRecruiting
Est. primary completion 2034-04-03 · NCT06133972 · CT.gov ↗
What to watch
2035 (1)
August 2035 (1)
Phase 3Lupus NephritisRecruiting
Est. primary completion 2035-08-01 · NCT06711887 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

12 August 2025Topline resultVAYHIT2 Phase III meets primary endpoint in ITP